[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 201
1. Wang Y, Ning X, Zhou J, Chen S: [Analysis of Treatment Response and Chest CT Characteristics for Patients treated by EGFR-TKI in Relapse Advanced Lung Adenocarcinoma.]. Zhongguo Fei Ai Za Zhi; 2008 Apr 20;11(2):236-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of Treatment Response and Chest CT Characteristics for Patients treated by EGFR-TKI in Relapse Advanced Lung Adenocarcinoma.].
  • BACKGROUND: For previously treated recurrent non-small cell lung cancer, many studies have proven that inhibitors of the tyrosine kinase of epidermal growth factor receptor (EGFR-TKI),such as gefitinib and erlotinib can increase survival, especially in non-smoker adenocarcinoma.
  • The objective of this study is to investigate the relationship between the characteristics of chest Computed tomography(CT) and objective response of gefitinib and erlotinib for recurrent lung adenocarcinoma.
  • METHODS: Thirty-seven patients with recurrent advanced lung adenocarcinoma were treated from Jan 1, 2004 to Mar 31, 2007 in our department.
  • Chest CT characteristic analysis showed that, the benefit rate was 79.9%(15/19)in patients with greater than 3 metastasis of lung or diffused disease, vs. 33.3%(6/18) in others,P <0.05; the benefit rate was 73.1%(19/26)and 67.4% (31/46)respectively in patients with pleural effusion and moderate contrast disease focus in enhancement CT scanning,vs. 22.2%(2/9)and 37.5%(9/24) in patients without pleural effusion and non-enhancement respectively,P <0.05.
  • CONCLUSIONS: For advanced lung adenocarcinoma, CT presentation of multiple metastasis of lung or diffused disease,pleural effusion and enhancing contrast disease focus may be a predictor for response when treated by EGFR-TKI.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731908.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, Lee DH, Suh C, Lee JS, Kim SW: [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res; 2008 Nov 15;14(22):7423-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
  • PURPOSE: To evaluate the usefulness of 3'-deoxy-3'-[18F]fluorothymidine (FLT)-positron emission tomography (PET) for predicting response and patient outcome of gefitinib therapy in patients with adenocarcinoma of the lung.
  • EXPERIMENTAL DESIGN: Nonsmokers with advanced or recurrent adenocarcinoma of the lung were eligible.
  • CONCLUSION: FLT-PET can predict response to gefitinib 7 days after treatment in nonsmokers with advanced adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Antineoplastic Agents / therapeutic use. Fluorine Radioisotopes. Lung Neoplasms / radionuclide imaging. Quinazolines / therapeutic use. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Nov 15;14(22):7159-60 [19010830.001]
  • (PMID = 19010859.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fluorine Radioisotopes; 0 / Quinazolines; 0 / Radiopharmaceuticals; S65743JHBS / gefitinib; VC2W18DGKR / Thymidine
  •  go-up   go-down


3. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M: Characterizing the cancer genome in lung adenocarcinoma. Nature; 2007 Dec 6;450(7171):893-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the cancer genome in lung adenocarcinoma.
  • Here we report a large-scale project to characterize copy-number alterations in primary lung adenocarcinomas.
  • By analysis of a large collection of tumours (n = 371) using dense single nucleotide polymorphism arrays, we identify a total of 57 significantly recurrent events.
  • We also identify 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions.
  • Only six of these focal events are currently associated with known mutations in lung carcinomas.
  • On the basis of genomic and functional analyses, we identify NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung adenocarcinomas.
  • More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered.


Advertisement
4. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM: Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res; 2007 May 15;13(10):2946-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression signature predicts recurrence in lung adenocarcinoma.
  • PURPOSE: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection.
  • EXPERIMENTAL DESIGN: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection.
  • CONCLUSIONS: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. Gene Expression Profiling. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102(s_supplement):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The lesions were primary in 86% and recurrent 14% of the cases; they were solitary in 31%, single in 29%, and multiple in 40%.
  • The most common histological types were adenocarcinoma (51%) and squamous cell carcinoma (27%).
  • Analysis of long-term outcomes seemed to confirm that GKS is a primary therapeutic option in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306429.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / non—small cell lung cancer
  •  go-up   go-down


6. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung.
  • CONTEXT: Primary lung cancer frequently metastasizes to distant organs; however, the pancreas is a relatively infrequent site of metastasis.
  • Most patients demonstrate accompanying metastases to other organs, especially in cases of lung cancer, which prove to be surgically unresectable when diagnosed.
  • Although several cases have been reported of patients who underwent pancreatic resection for curative intent, most patients died from recurrent disease.
  • CASE REPORT: We report herein an unusual case of secondary tumor of the pancreas (primary tumor: adenocarcinoma of the lung) with hopefully curative resection.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Fujimoto N, Kiura K, Takigawa N, Fujiwara Y, Toyooka S, Umemura S, Tabata M, Ueoka H, Tanimoto M: Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. Acta Med Okayama; 2010 Feb;64(1):33-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
  • We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
  • Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / mortality. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Quinazolines / adverse effects. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200582.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Quinazolines; 0 / Taxoids; 0H43101T0J / irinotecan; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Job B, Bernheim A, Beau-Faller M, Camilleri-Broët S, Girard P, Hofman P, Mazières J, Toujani S, Lacroix L, Laffaire J, Dessen P, Fouret P, LG Investigators: Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One; 2010;5(12):e15145
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic aberrations in lung adenocarcinoma in never smokers.
  • BACKGROUND: Lung cancer in never smokers would rank as the seventh most common cause of cancer death worldwide.
  • METHODS AND FINDINGS: We performed high-resolution array comparative genomic hybridization analysis of lung adenocarcinoma in sixty never smokers and identified fourteen new minimal common regions (MCR) of gain or loss, of which five contained a single gene (MOCS2, NSUN3, KHDRBS2, SNTG1 and ST18).
  • NSD1 and FUS are oncogenes hitherto not known to be associated with lung cancer.
  • SNP array analysis validated copy-number aberrations and revealed that RB1 and WRN were altered by recurrent copy-neutral loss of heterozygosity.
  • Multiple genetic pathways defined by gains of MYC, deletions of RB1 and WRN or gains on 7p and 7q are involved in lung adenocarcinoma in never smokers.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genomics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1309-13 [11245426.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4464-8 [12154056.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6877-83 [12362270.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1263-70 [12599234.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Nature. 1983 Oct 27-Nov 2;305(5937):779-84 [6633649.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):721-9 [9989822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1136-48 [16899659.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):469-71 [17290053.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):472-8 [17290054.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):561-70 [17290066.001]
  • [Cites] J Clin Pathol. 2007 Apr;60(4):337-40 [16916998.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Apr 1;182(1):1-11 [18328944.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5731-4 [18794081.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):216-24 [19212324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7 [19279207.001]
  • [Cites] Nature. 2009 Jun 25;459(7250):1085-90 [19553991.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(13):4181-93 [19570852.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5622-5 [19755390.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5646-61 [19755392.001]
  • [Cites] J Mol Cell Biol. 2009 Dec;1(2):82-92 [19783543.001]
  • [Cites] Nature. 2010 Jan 14;463(7278):184-90 [20016488.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4806-12 [15870700.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8235-42 [16322280.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1371-5 [16452191.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1700-4 [16505411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8822-7 [16723399.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9295-302 [15489893.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • (PMID = 21151896.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2997777
  • [Investigator] Dartevelle P; Dulmet E; Leroy-Ladurie F; de Montpreville V; Monnet I; Bernard A; Piard F; Alifano M; Camilleri-Broët S; Régnard JF; Hofman P; Hofman V; Mouroux J; Trédaniel J; Beau-Faller M; Massard G; Neuville A; Antoine M; Cadranel J; Brouchet L; Mazières J; Rouquette I; Saint-Blancard P; Vaylet F; Berhneim A; Dessen P; Dufour F; Dorvault N; Fouret P; Job B; Lacroix L; Lazar V; Richon C; Roux V; Saulnier P; Taranchon E; Toujani S; Valent A; Girard P; Gossot D; Validire P; Laffaire J
  •  go-up   go-down


9. Charoentum C: Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year. J Med Assoc Thai; 2006 Jun;89(6):882-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
  • A 53-year old non-smoking Thai female was diagnosed with metastatic non-small cell lung cancer to bone.
  • The initial biopsy from the bone lesion showed metastatic adenocarcinoma.
  • This result is consistent with previous reports that the clinical characteristics of female, non-smoker and adenocarcinoma histology seem to predict response to gefitinib.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850692.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


10. Kasai T, Kishi K, Kawabata M, Narui K, Momomura S, Yoshimura K: Cardiac metastasis from lung adenocarcinoma causing atrioventricular block and left ventricular outflow tract obstruction. Chest; 2007 May;131(5):1569-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis from lung adenocarcinoma causing atrioventricular block and left ventricular outflow tract obstruction.
  • Cardiac metastasis from lung cancer is rarely diagnosed antemortem, as it usually causes no symptoms or signs.
  • We report the case of a 56-year-old man with recurrent lung adenocarcinoma in whom developed a large mass in the ventricular septum, complete atrioventricular block, and obstruction of the left ventricular outflow tract.
  • [MeSH-major] Adenocarcinoma / secondary. Heart Block / etiology. Heart Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494807.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Shoji F, Yano T, Yoshino I, Mori D, Yamasaki F, Kohno H, Maehara Y: The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. Eur J Surg Oncol; 2008 Jan;34(1):89-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
  • AIMS: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC).
  • We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib.
  • METHODS: From 2002 to 2006, gefitinib was administered to in 34 postoperative recurrent lung adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / complications. Postoperative Care. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449217.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


12. Ohgi M, Endo S, Tsubochi H, Sohara Y, Watanabe Y, Koyama S, Hiroshima K: [Localized pleural adenocarcinoma]. Kyobu Geka; 2007 Feb;60(2):112-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized pleural adenocarcinoma].
  • We report a 58-year-old male with localized pleural adenocarcinoma, the origin of which was not identified.
  • A fine needle biopsy showed adenocarcinoma, but whole body survey revealed no neoplasm other than the chest wall tumor.
  • Pathological examinations showed no primary tumor in the lung.
  • Immunohistochemical examinations suggested that micro-adenocarcinoma originating the subpleural lung invaded chest wall.
  • It may be possibly a subtype of pseudomesotheliomatous adenocarcinoma.
  • The patient has no recurrent tumor 1 year after the operation.
  • [MeSH-major] Adenocarcinoma / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305076.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Yuba T, Nagata K, Shiotsu S, Okano A, Hatsuse M, Murakami S, Morihara K, Shimazaki C: [Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):81-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Erlotinib Hydrochloride. Female. Humans. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163028.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


14. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K: Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer; 2010 Sep;69(3):361-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
  • The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer.
  • The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS.
  • Here, we report a case of EML4-ALK-positive lung adenocarcinoma that showed multiple metachronous lesions on the pleura and pulmonary field, suspected to be a recurrence of lung adenocarcinoma after a 20-year disease-free interval.
  • The slow clinical course may be characteristic of EML4-ALK-positive lung adenocarcinoma.
  • Therefore, long-term observation of patients with EML4-ALK-positive lung adenocarcinomas is required after surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20659620.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


15. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).
  • Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gamaz MB, Bouzid K: Use of gemcitabine plus vinorelbine (GV) to treat advanced and metastatic non-small cell lung cancer (NSCLC) in second line after recurrent disease. J Clin Oncol; 2009 May 20;27(15_suppl):e19104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of gemcitabine plus vinorelbine (GV) to treat advanced and metastatic non-small cell lung cancer (NSCLC) in second line after recurrent disease.
  • Squamous cell cancer was found in 12 patients, adenocarcinoma in 11 patients.
  • CONCLUSIONS: Gemcitabine + Vinorelbine could be another alternative for treatment of NSCLC in second line after recurrent disease when first line chemotherapy is platine + docetaxel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963044.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Laskin JJ, Pugh T, Jackson C, Sutcliffe M, Ionescu D, Melosky B, Ho C, Sun S, Murray N, Marra M: Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer.
  • Eligibility criteria included: stage IIIB/IV NSCLC; no prior chemo; ECOG ≤2; at least 2 of the following 4 criteria: women, never-smokers, Southeast Asian origin, adenocarcinoma and/or BAC.
  • Full tumour RNA analysis identified several recurrent mutations that may describe mechanisms of erlotinib response and resistance.
  • The discovery of novel mutations in multiple pts suggests patterns that may shed light on lung cancer specific behaviour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kim ES, Herbst RS, Lee JJ, Blumenschein G, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, Hong WK: Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol; 2009 May 20;27(15_suppl):8024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program.
  • : 8024 Background: Treatment for patients (pts) with recurrent NSCLC has limited efficacy despite the use of new targeted agents.
  • 112 of the biopsied lesions were lung, with a pneumothorax rate of 12.1% (15 of 124 pts; grade 1-2 only; lung, mediastinal and pleural sites).
  • HISTOLOGY: adenocarcinoma (75%), squamous (11%), large cell (13%).
  • BATTLE is one of the first studies in advanced lung cancer to prospectively utilize biomarker analysis of fresh biopsies to direct pt treatment, and is a step towards personalizing therapy in NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962837.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Han J, Lee S, Yun T, Moon Y, Park I, Kim H, Lee J: Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC).
  • This study compared gefitinib alone with gefitinib plus simvastatin in patients with recurrent NSCLC after at least one chemotherapy.
  • METHODS: Between May 2006 and September 2008, 107 patients (51% male, 74% adenocarcinoma, 50% never-smoker, 54% more than two prior regimens) were randomly assigned to gefitinib alone (250 mg/d orally, n=53) or gefitinib plus simvastatin (250mg/d and 40 mg/d orally, respectively, n=54).
  • In subgroup analysis, gefitinib plus simvastatin showed a trend for higher RR than gefitinib alone in non-adenocarcinoma group (38.5% vs. 7.7%, p=0.08).
  • CONCLUSIONS: Gefitinib combined with simvastatin did not improved efficacy compared to gefitinib alone in this unselected patient population, but showed a trend for higher efficacy in non-adenocarcinoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gadgeel SM, Wozniak A, Edelman MJ, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, Shields A, LoRusso P, Hackstock D, Ruckdeschel J: Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
  • : e19007 Background: There are only limited data regarding the use of anti-VEGF therapy in recurrent NSCLC and no data in NSCLC pts previously treated with bevacizumab.
  • We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1,2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab.
  • RESULTS: 33 pts have started therapy, (Cohort A- 20, Cohort B- 13), median age- 60, males- 56%, ever smokers- 88%, adenocarcinoma- 64%, squamous- 12%, brain mets- 27%, 1 prior regimen- 52%, PS0-1- 88%.
  • Efficacy has been observed with the combination in recurrent NSCLC pts, including those previously treated with bevacizumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962508.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Key eligibility criteria were untreated locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0-2, tumor not abutting major blood vessels, no uncontrolled HTN (systolic >150mmHg and/or diastolic >100mmHg) or active cardiovascular disease at baseline.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Crino L, Mezger J, Griesinger F, Zhou C, Reck MM: MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • Pts with untreated locally advanced, metastatic or recurrent non-squamous NSCLC (ECOG PS 0-2) received Bv (7.5 or 15mg/kg) with standard chemotherapy for up to six cycles, then non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • Erlotinib is an EGFR TKI that prolongs survival in p with recurrent and metastatic NSCLC.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Manson GV, Ma PC: Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. Clin Lung Cancer; 2010 Jan;11(1):57-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
  • Targeted therapy against epidermal growth factor receptor (EGFR) in non-small-cell lung cancer has heralded an era of mutationally targeted inhibition of this receptor and its oncogenic signal transduction using the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib.
  • Herein, we report a case of a patient with recurrent metastatic lung adenocarcinoma-bronchioloalveolar carcinoma that showed primary insensitivity to erlotinib therapy who later demonstrated substantial durable response to single-agent pemetrexed.
  • We also present discussion on the evolving paradigm of the use of erlotinib in lung cancer and the current status of determinants of sensitivity in pemetrexed chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Pemetrexed. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Quinazolines / pharmacology. Quinazolines / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085869.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


25. Royter V, Cohen SN: Recurrent embolic strokes and cardiac valvular disease in a patient with non-small cell adenocarcinoma of lung. J Neurol Sci; 2006 Feb 15;241(1-2):99-101
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent embolic strokes and cardiac valvular disease in a patient with non-small cell adenocarcinoma of lung.
  • Cerebrovascular disease in cancer patients is often aggressive with tendency to recurrent events and rapid neurological devastation.
  • We report a case of multiple embolic strokes in a patient diagnosed with lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Heart Valve Diseases / etiology. Lung Neoplasms / complications. Stroke / etiology

  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318856.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Shitara K, Munakata M, Ishiguro A, Kudo T, Okada R, Tomioka R, Mitobe S, Yokoyama S, Sakata Y: [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1497-1500
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
  • CASE REPORT: A 53-year-old woman was treated with combination chemotherapy of irinotecan plus cisplatin for a recurrent ovarian clear cell adenocarcinoma.
  • Emergency laparotomy was not performed because of poor performance status with multiple lung metastases, pleural effusion and pericardial effusion.
  • Colonoscopy showed a perforated wall at the cecum, and a long tube with balloon was inserted for occlusion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Diseases / etiology. Intestinal Perforation / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colonoscopy. Drainage. Drug Administration Schedule. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033246.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


27. Okagawa T, Uchida T, Suyama M: [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1841-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
  • A 70-year-old woman underwent a right middle lobectomy and partial resection of right upper lobe for lung cancer.
  • The pathological findings were well-differentiated adenocarcinoma, pT2N0M0, Stage IB.
  • We diagnosed it as a recurrence of the lung cancer.
  • Then, 1 month after beginning gefitinib, her serum CEA level normalized and the recurrent lesion disappeared on chest CT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030020.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


28. Okamoto T, Maruyama R, Seto T, Yamazaki K, Wataya H, Nishiyama K, Ichinose Y: Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy. Lung Cancer; 2007 Jun;56(3):449-53
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy.
  • Pulmonary metastases (PM) to different lobes are classified as M1 disease in non-small cell lung cancer.
  • We report on three patients with lung adenocarcinoma who had undergone complete resection as the initial treatment and thereafter had recurrence of multiple PMs but only in a different ipsilateral lobe 19, 9, and 6 months after surgery.
  • Two patients underwent completion pneumonectomy for the ipsilateral recurrent PM and are doing well without recurrence at 7 and 1 year after the second operations.
  • Our findings suggest that some patients with recurrent multiple PM limited to a different ipsilateral lobe have a good prognosis with aggressive treatment, including surgery, and suggest that the PM in such patients occurs through a local route within the ipsilateral thorax.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Neoplasm Recurrence, Local. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300852.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


29. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH: Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol; 2007 Jan;62(1):28-34; discussion 35-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.
  • AIM: To evaluate patterns of disease and identify factors predicting outcome in patients presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • MATERIALS AND METHODS: A retrospective review was performed of the imaging and clinical data in 86 patients (median age 66 years, range 42-88 years) presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • RESULTS: Following primary surgery recurrent disease occurred within 2 years in 64% and within 3 years in 87%.
  • Relapse was seen within lymph nodes in 41 (46%), the vagina in 36 (42%) the peritoneum in 24 (28%) and the lung in 21 (24%).
  • The presence of disease within the vagina, bladder or lung was not associated with poor prognosis.
  • CONCLUSION: The most frequently observed sites of relapse are: lymph nodes, vagina, peritoneum and lung.
  • Significant predictors of poor outcome in recurrent disease are multiple sites of disease and liver and splenic metastases.
  • [MeSH-major] Adenocarcinoma / radiography. Endometrial Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Splenic Neoplasms / radiography. Splenic Neoplasms / secondary. Vaginal Neoplasms / radiography. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145260.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Takakuwa O, Oguri T, Sato S, Nakao M, Ohta C, Iwashima Y, Miyazaki M, Maeno K, Kutsuna T, Nakamura A, Ueda R: [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1721-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
  • There is at present no defined role for S-1 chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who previously failed chemotherapy.
  • A 75-year-old man was diagnosed as having pulmonary adenocarcinoma, cT1N3M0, stage III B.
  • After completing two courses, chest computed tomography(CT)showed a partial response( PR)of the recurrent tumors, and the serum carcinoembryonic antigen level decreased.
  • A 65-year-old woman was referred for treatment of recurrent pulmonary adenocarcinoma after right upper lobe resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838034.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


31. Hanaoka T, Sone S, Yamaguchi S, Okada M, Hayano T: [An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1701-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].
  • An 82-year-old woman, a never smoker, had a radical operation for CT screening revealed lung cancer in an other hospital in 1997.
  • She was diagnosed to have a local recurrence of lung cancer 6 years after the operation.
  • It will be useful as a treatment option for octogenarians having postoperative recurrent lung cancers with every other day administration of gefitinib.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940395.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


32. Togashi K, Hosaka Y, Okada A, Sato S: [Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection]. Kyobu Geka; 2010 Oct;63(11):963-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection].
  • During a 24-year period (1986-2009), 74 patients (3.5%) underwent iterative surgical resections for 2nd primary and recurrent lung cancer.
  • Patients are classified to 5 groups: 20 2nd primary lung cancer patients undergoing lobectomy (A), 24 2nd primary lung cancer patients undergoing limited resection (B), 11 2nd primary bronchioloalveolar carcinoma (BAC) patients undergoing limited resection (C), 8 recurrent lung cancer patients undergoing lobectomy (D), and 11 recurrent lung cancer patients undergoing limited resection (E).
  • There were 18 (90%) patients with adenocarcinoma in group A, 15 (63%) in B, 11 (100%) in C, 5 (63%) in D, and 9 (82%) in E.
  • These data showed that limited resections had low surgical risk and good long-term results.
  • Limited resection appears to achieve better outcomes for 2nd primary and recurrent lung cancer and should be chosen whenever possible.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954351.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Wright ZM, Fryer JS, Calise DV, Oliveira FN: Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma. J Am Anim Hosp Assoc; 2010 Jan-Feb;46(1):66-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma.
  • The mass was incompletely excised, and histological assessment resulted in a diagnosis of anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Anal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cat Diseases / drug therapy
  • [MeSH-minor] Anal Sacs / pathology. Animals. Cats. Fatal Outcome. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045840.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


34. Kawashima O, Ibe T, Kakegawa S, Nakano T, Shimizu K: [Surgical treatment and outcome for postoperative recurrent or second primary lung cancer]. Kyobu Geka; 2010 Oct;63(11):935-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and outcome for postoperative recurrent or second primary lung cancer].
  • From 2000 to 2009, we retrospectively reviewed 62 patients who underwent surgical treatment for postoperative recurrent or 2nd primary lung cancer.
  • The histology of the initial primary lung cancer was adenocarcinoma in 42 patients, squamous cell carcinoma in 18, large cell carcinoma in 1 and small cell carcinoma in 1.
  • The surgical procedures for 1st operation were lobectomy with mediastinal lymph node dissection in 52, bilobectomy with mediastinal lymph node dissection in 4, sleeve lobectomy with mediastinal lymph node dissection in 3, and lobectomy + segmentectomy or wedge resection with mediastinal lymph node dissection in 3. p-stage of the 1st primary lung cancer was IA in 22, IB in 16, II A in 7, IIB in 6, IIIA in 6, IIIB in 4, and IV in 1.
  • Of these, 42 patients were diagnosed 2nd primary lung cancer, 20 patients were recurrent disease histologically.
  • The 5-year survival rate of the patients with metachronous and recurrent disease from the 2nd operation was 54.1%, and 43.1%, respectively.
  • Although lobectomy or CP should be considered the surgical procedure of choice for patients with metachronous lung cancer, with this result, we consider that postoperative good survival can be expected by even the limited operation for cases of postoperative recurrent or 2nd primary lung cancer because of possible early detection.
  • We conclude that limited surgery may be a treatment of choice for recurrent or 2nd primary lung cancer after initial operation.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954346.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Hirose T, Hosaka T, Nakashima M, Sugiyama T, Ishida H, Yamaoka T, Okuda K, Adachi M: [Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1]. Gan To Kagaku Ryoho; 2008 Feb;35(2):327-30
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1].
  • We report two cases with recurrent non-small cell lung cancer (NSCLC) successfully treated with cisplatin and S-1 after multiple chemotherapy.
  • A 64-year-old woman was diagnosed with adenocarcinoma, yield-T4N2M1, stage IV.
  • Chest computed tomography (CT) showed partial response of recurrent tumors.
  • Another woman (56 years old) was diagnosed with adenocarcinoma, yield-T0N1M1, stage IV.
  • Chest CT showed a partial response of recurrent tumors.
  • Additionally, we retrospectively reviewed 10 cases with recurrent NSCLC treated with cisplatin and S-1 during the same period.
  • Cisplatin combined with S-1 could be an option for recurrent NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281776.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Katayama T, Matsuo K, Kosaka T, Sueda T, Yatabe Y, Mitsudomi T: Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. Surg Oncol; 2010 Dec;19(4):e144-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
  • BACKGROUND: Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib.
  • METHODS: A total of 304 patients with lung adenocarcinoma who had postoperative recurrent disease were studied.
  • CONCLUSIONS: This study strongly suggested that gefitinib treatment improved OS of lung adenocarcinoma patients who had postoperative recurrence, especially those carrying EGFR mutations.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20705455.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


37. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Middle Aged. Receptors, Estrogen / metabolism. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


38. Iwata T, Inoue K, Morita R, Tsukioka T, Yamoto M, Suehiro S: Acute nonbacterial pleuritis caused by spontaneous rupture of metastatic pulmonary adenocarcinoma. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):347-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute nonbacterial pleuritis caused by spontaneous rupture of metastatic pulmonary adenocarcinoma.
  • Nonbacterial pleuritis caused by rupture of a metastatic adenocarcinoma is extremely rare and has not yet been reported.
  • A 59-year-old man with a history of rectal cancer surgery 6 years earlier presented with a solitary lung mass in the periphery of the right lower lobe on computed tomography.
  • Transbronchial biopsy disclosed a suspected metastatic adenocarcinoma, and he was admitted for pulmonary metastasectomy.
  • The postoperative course was uneventful, and he was well without recurrent disease 2 years after pulmonary resection.
  • [MeSH-major] Adenocarcinoma / complications. Colorectal Neoplasms / pathology. Lung Neoplasms / complications. Pleurisy / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2006;36(10):919-22 [16998687.001]
  • [Cites] J Am Geriatr Soc. 2006 May;54(5):827-30 [16696751.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1865-6 [8792722.001]
  • [Cites] Surg Today. 2000;30(5):469-72 [10819490.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1734-7 [6950803.001]
  • (PMID = 18607683.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


39. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study and review of polymorphous low-grade adenocarcinoma.
  • OBJECTIVES/HYPOTHESIS: We review a single institution's experience with polymorphous low-grade adenocarcinoma.
  • To our knowledge, this is the largest patient series of polymorphous low-grade adenocarcinoma with clinical follow-up in the otolaryngology literature.
  • STUDY DESIGN: We retrospectively identified 19 patients with polymorphous low-grade adenocarcinoma who had adequate clinical follow-up and pathologic specimens available for examination.
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • Five patients had a local recurrence after surgery; of those patients, two had initially presented with recurrent tumors.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • The most common initial diagnoses were polymorphous low-grade adenocarcinoma, adenoid cystic carcinoma, and pleomorphic adenoma.
  • CONCLUSIONS: Polymorphous low-grade adenocarcinoma is an increasingly recognized malignancy that originates predominantly in the minor salivary gland.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology


40. Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H, Maehara Y: Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer; 2007 Dec 15;110(12):2793-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.
  • BACKGROUND: The presence of epidermal growth factor receptor (EGFR) gene mutations is a good indicator of the clinical efficacy of gefitinib in patients with nonsmall cell lung cancer.
  • The current study analyzed the association between EGFR gene mutations and clinical features, including the serum CEA level, in patients with recurrent lung adenocarcinomas.
  • METHODS: A total of 48 lung adenocarcinoma patients with postoperative disease recurrence who underwent chemotherapy were investigated.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / genetics. Carcinoembryonic Antigen / blood. Genes, erbB-1. Lung Neoplasms / blood. Lung Neoplasms / genetics. Mutation. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17941001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


41. Nishimoto J, Amoh Y, Niiyama S, Takasu H, Katsuoka K: Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases. J Dermatol; 2008 Jul;35(7):468-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases.
  • A 41-year-old Japanese male had aggressive digital papillary adenocarcinoma with pulmonary metastases.
  • Five years after the initial removal of the lesion, the patient was referred to our hospital because of a recurrent skin nodule on his left palm.
  • The recurrent skin tumor was found to have lobular proliferation of anaplastic cells.
  • The tumor was diagnosed as an aggressive digital papillary adenocarcinoma.
  • This report is a rare case of aggressive digital papillary adenocarcinoma that was diagnosed based on the histopathology of the pulmonary metastases, which showed ductal structures associated with papillary projections.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705837.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Brahmania M, Kanthan CS, Kanthan R: Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor. World J Surg Oncol; 2007;5:118
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor.
  • We report the first case, to our knowledge in the English literature, of a collision tumor composed of a colonic adenocarcinoma arising in a sigmoid diverticulum coexisting with a recurrent ovarian granulosa cell tumor.
  • Surgical removal of the mass and pathological examination revealed the presence of a colonic adenocarcinoma arising in a large sigmoid diverticulum coexistent with a second neoplastic tumor phenotype; confirmed to be a delayed recurrent ovarian granulosa cell tumor.
  • She developed lung metastases from the recurrent ovarian tumor within 6 months and died within a year of follow-up.
  • This is the first case reported of a collision tumor composed of adenocarcinoma colon and recurrent granulosa cell tumor representing an example of two independent tumors in a unique one-on-another collision.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ceska Gynekol. 2000 May;65(3):163-6 [10953492.001]
  • [Cites] Rom J Morphol Embryol. 2007;48(1):75-8 [17502956.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1976 Jul;38(1):335-40 [181131.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surgery. 1993 Feb;113(2):223-6 [8430371.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):71-7 [8121188.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):538-9 [8870012.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • [Cites] Arch Pathol Lab Med. 1998 Mar;122(3):262-5 [9823866.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):11-25 [15777886.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2758-9 [12498297.001]
  • (PMID = 17949502.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164962
  •  go-up   go-down


43. Kimura A, Hiramatsu K, Sakuragawa T, Ito T, Otsuji H, Tsuchiya T, Hara T, Maeda T, Tanaka H, Machiki Y, Hosoya J, Kojima T, Kato K: [A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operation]. Gan To Kagaku Ryoho; 2010 Feb;37(2):303-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operation].
  • About one year after the operation, lung metastasis was recognized by enhanced CT examination.
  • The metastastic tumor of the lung disappeared at the time of discharge.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Empyema, Pleural / complications. Esophageal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154490.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Godoy T C, Vega S J, Rivera G L: [Recurrent left lung atelectasis caused by an endobronchial metastasis of a colon cancer: report of one case]. Rev Med Chil; 2008 Feb;136(2):217-20
MedlinePlus Health Information. consumer health - Collapsed Lung.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent left lung atelectasis caused by an endobronchial metastasis of a colon cancer: report of one case].
  • [Transliterated title] Atelectasia pulmonar recurrente secundaria a una metástasis endobronquial de un carcinoma de colon: Caso clínico.
  • We report an 83 year-old woman with a history of a left hemicolectomy due to tubular colon adenocarcinoma, three years ago.
  • Chest X ray examination showed a complete opacity of the left lung.
  • She was treated as a pneumonia and her left lung expanded again.
  • Three weeks later, left lung atelectasis relapsed.
  • A bronchial biopsy showed a moderately differentiated adenocarcinoma, compatible with colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Bronchial Neoplasms / secondary. Colonic Neoplasms / pathology. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483676.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


45. Suzuki A, Shijubo N, Yamada G, Ichimiya S, Satoh M, Abe S, Sato N: Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract; 2005;201(8-9):579-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs.
  • The aim of the present study was to compare the usefulness of the peripheral airway cell markers, naspin A and surfactant protein A (SP-A), for distinguishing primary lung adenocarcinoma from adenocarcinomas of other organs in various clinical conditions.
  • Immunohistochemical expression of napsin A and SP-A was analyzed at primary sites of 120 lung carcinomas and 40 adenocarcinomas of other organs, at lung metastatic sites of 32 adenocarcinomas of other organs, and in metastatic lymph nodes of 21 lung adenocarcinomas and 45 adenocarcinomas of other organs.
  • Napsin A and SP-A expressions were compared between primary and recurrent sites in 8 lung adenocarcinomas.
  • Napsin A and SP-A expressions were noted in 84.3% and 53.0% of primary sites of 83 lung adenocarcinomas, respectively, but neither napsin A nor SP-A was expressed at primary sites of other histological types of lung carcinomas or at primary or metastatic sites of adenocarcinomas of other organs.
  • In lung adenocarcinomas, napsin A and SP-A were expressed in metastatic lymph nodes in 81.0% and 19.0%, respectively, and at recurrent sites in 87.5% and 37.5%, respectively.
  • Napsin A is superior to SP-A for distinguishing primary lung adenocarcinoma from adenocarcinomas of other organs at primary, metastatic, and recurrent sites.
  • [MeSH-major] Adenocarcinoma / diagnosis. Aspartic Acid Endopeptidases / metabolism. Lung Neoplasms / diagnosis. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259111.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pulmonary Surfactant-Associated Protein A; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


46. Gelpke H, Grieder F, Decurtins M, Cadosch D: Recurrent laryngeal nerve monitoring during esophagectomy and mediastinal lymph node dissection. World J Surg; 2010 Oct;34(10):2379-82
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent laryngeal nerve monitoring during esophagectomy and mediastinal lymph node dissection.
  • BACKGROUND: Patients who undergo surgery to the esophagus and lungs are in jeopardy of recurrent laryngeal nerve (RLN) damage during the procedure.
  • This study was designed to investigate the feasibility of intraoperative monitoring of the RLN for single-lung ventilation esophagus and lung surgery.
  • METHODS: Twelve consecutive patients booked for esophagus or lung surgery were included in this prospective, observational study.
  • Six patients underwent transthoracic esophagectomy for carcinoma of the esophagogastric junction or lower esophagus, five had a lobectomy, and one underwent a pneumonectomy for lung carcinoma.
  • CONCLUSIONS: Intraoperative RLN identification and monitoring during single-lung ventilation surgery is technically feasible, easy, and reliable.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Lymph Node Excision / adverse effects. Recurrent Laryngeal Nerve Injuries. Vocal Cord Paralysis / prevention & control
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Feasibility Studies. Female. Humans. Lung Neoplasms / surgery. Male. Mediastinum. Middle Aged. Monitoring, Intraoperative. Pneumonectomy / adverse effects. Prospective Studies. Recurrent Laryngeal Nerve / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2012 Dec;36(12):2946-7; author reply 2948 [22736347.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Oct;20(4):705-11 [11574212.001]
  • [Cites] Dis Esophagus. 2007;20(3):206-11 [17509116.001]
  • [Cites] Am J Otolaryngol. 2006 Mar-Apr;27(2):106-8 [16500473.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):9-17 [15213612.001]
  • [Cites] Chirurg. 2000 May;71(5):545-50 [10875012.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Feb;37(1):25-44, v [15062685.001]
  • [Cites] Lancet. 1956 Sep 29;271(6944):638-41 [13368480.001]
  • [Cites] J Am Coll Surg. 1994 Jun;178(6):605-8 [8193754.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):155-60 [11177032.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):277-81 [15780563.001]
  • [Cites] Surgery. 2004 Dec;136(6):1310-22 [15657592.001]
  • (PMID = 20563722.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Parsons CM, Sutcliffe JL, Bold RJ: Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg; 2008;15(4):429-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of pancreatic adenocarcinoma.
  • Although 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been demonstrated to be useful in the staging of many malignancies (e.g. esophageal cancer, recurrent colorectal cancer, lung cancer), it has not been found to significantly increase the accuracy of determining resectability preoperatively in pancreatic cancer, especially with regard to detection of small volume metastatic disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670846.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Glucose Transporter Type 1; 0 / Integrin alphaV; 40871-47-4 / 2-fluoro-2-deoxyglucose-6-phosphate; 56-73-5 / Glucose-6-Phosphate
  • [Number-of-references] 72
  •  go-up   go-down


48. Minami K, Kameda A, Tsutani Y, Suzuki T, Miyahara E, Noso Y: [Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer]. Gan To Kagaku Ryoho; 2007 Apr;34(4):573-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
  • FOLFOX regimens were administered to 14 patients with unresectable advanced or recurrent colorectal cancer from 1 to 9 cycles (median 5 cycles).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Anorexia / chemically induced. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431362.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


49. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol; 2010 Oct 20;28(30):4616-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
  • PURPOSE: To determine the proportion of lung adenocarcinomas from East Asian never-smokers who harbor known oncogenic driver mutations.
  • PATIENTS AND METHODS: In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
  • Thus, 90% (47 of 52; 95% CI, 0.7896 to 0.9625) of lung adenocarcinomas from never-smokers were found to harbor well-known oncogenic mutations in just four genes.
  • CONCLUSION: To our knowledge, this study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Tob Control. 2004 Mar;13 Suppl 1:i57-60 [14985618.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1700-4 [16505411.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):209-15 [16930767.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):245-52 [18594528.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4877-82 [18676761.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6913-21 [18757405.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3199-208 [18932251.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3143-9 [19383809.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Oncogene. 2009 Aug 6;28(31):2773-83 [19525976.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5626-45 [19755391.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1466-76 [19737969.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):755-63 [20068085.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):121-8 [20022809.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • (PMID = 20855837.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA90949; United States / NCI NIH HHS / CA / R01 CA121210; United States / NCI NIH HHS / CA / P50 CA090949; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / CA68485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2974342
  •  go-up   go-down


50. Lee DH, Han JY, Kim HT, Lee JS: Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer; 2006 Sep;53(3):339-45
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
  • We analyzed data from 575 patients with advanced or metastatic non-small cell lung cancer treated with gefitinib in National Cancer Center, Goyang, Korea between 2002 and 2005.
  • The median survival time calculated from the first diagnosis of advanced/metastatic disease or recurrent disease was 21.6 months.
  • In a multivariate logistic regression model, adenocarcinoma histology, smoking history, performance status, and history of prior chemotherapy were statistically significant predictors for tumor response to gefitinib.
  • The response rate of the most favorable subgroup, chemotherapy-naive never-smokers with adenocarcinoma, was 52.2% (95% CI, 42.6-61.7).
  • In a multivariate Cox proportional hazard model, performance status, adenocarcinoma histology, and history of prior chemotherapy were the independent predictors of survival (p<0.001, p<0.001, and p=0.002, respectively).
  • This retrospective analysis suggests that gefitinib was of great benefit for chemotherapy-naive patients who had good performance status and adenocarcinoma histology.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824646.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


51. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • Fine needle aspiration biopsy of the lung lesions showed round to oval tumor cells with amphophilic cytoplasm.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • A 39-yr-old, acyclic, uniparous, female white rhinoceros with a history of recurrent vaginal bleeding was euthanized following a period of respiratory distress and ill-thrift.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, Zhou Z, Nikitin AY, Roy-Burman P: Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res; 2007 Aug 1;67(15):7525-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
  • Here, we describe the improvement of the conditional Pten deletion model of prostate adenocarcinoma by combining it with either a conditional luciferase or enhanced green fluorescent protein reporter line.
  • By comparing the distribution of phenotypically distinct populations of epithelial cells in cancer tissues, we noted that the degree of hyperplasia of cells with neuroendocrine differentiation significantly increases in the recurrent cancer relative to the primary cancer, a characteristic which may parallel the appearance of a neuroendocrine phenotype in human androgen depletion-independent cancer.
  • [MeSH-major] Fluorescent Antibody Technique. Image Interpretation, Computer-Assisted. Luminescent Measurements. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Prostatic Neoplasms / pathology


54. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F, Xu GC, Zhang L, Guan ZZ: [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):148-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
  • OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of Gefitinib in the treatment of Chinese patients with recurrent advanced non-small-cell lung cancer (NSCLC).
  • The results of COX model analysis suggested that the patients with adenocarcinoma, rash and favourable performance status (PS) had longer TTP.
  • CONCLUSION: Gefitinib is effective in treatment of patient with recurrent advanced NSCLC.
  • The patients with controlled disease may achieve a long survival, and the adverse reactions are mild and tolerable.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538895.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


55. Navi BB, DeAngelis LM, Segal AZ: Multifocal strokes as the presentation of occult lung cancer. J Neurooncol; 2007 Dec;85(3):307-9
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal strokes as the presentation of occult lung cancer.
  • These atypical features prompted a malignancy evaluation which revealed an occult lung adenocarcinoma.
  • Our patient had a rapidly deteriorating course with recurrent strokes despite numerous anti-platelet and anti-coagulant agents, and was only responsive to chemotherapy aimed at the underlying cancer.
  • [MeSH-major] Adenocarcinoma / complications. Infarction, Middle Cerebral Artery / etiology. Lung Neoplasms / complications. Stroke / etiology. Thrombophilia / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] An Med Interna. 2004 Oct;21(10):495-7 [15511201.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):267-9 [15735915.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2025-30 [15184609.001]
  • [Cites] Arch Neurol. 1976 Apr;33(4):260-4 [1259640.001]
  • [Cites] Am J Med. 1987 Oct;83(4):746-56 [3674060.001]
  • [Cites] Schweiz Arch Neurol Psychiatr (1985). 1988;139(2):5-11 [2455936.001]
  • [Cites] Medicine (Baltimore). 1985 Jan;64(1):16-35 [3965856.001]
  • (PMID = 17611718.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


56. Guandalini M, Steinke K, Francesconi A: Pulmonary metastases from cervical adenocarcinoma regress to a 'hole' lot of nothing. J Thorac Oncol; 2009 Apr;4(4):552-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastases from cervical adenocarcinoma regress to a 'hole' lot of nothing.
  • A 38-year-old woman with recurrent metastatic cervical adenocarcinoma developed innumerable bilateral solid and cavitating pulmonary metastatic nodules.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333074.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Miller JC, Blake DC Jr, Herzog CR: Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma. Mol Carcinog; 2009 Dec;48(12):1116-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma.
  • Tobacco smoke consists of numerous carcinogens whose effect on lung tumor development includes the induction of mutations in key genes as well as the induction of chromosome instability (CIN).
  • Consequently, carcinogen-induced mouse lung adenocarcinomas (LAC) display many more recurrent site- and chromosome-specific changes in DNA copy number compared with noninduced LAC.
  • A similar frequency of ADSS1 deletion was observed in human LAC cell lines, suggesting relevance in human lung cancer.
  • These results implicate ADSS1 inactivation as a novel somatic alteration in lung carcinogenesis, and suggest that its selective deletion in LAC may be triggered by CIN.
  • [MeSH-major] Adenocarcinoma / genetics. Adenylosuccinate Synthase / genetics. Chromosomal Instability / genetics. Gene Deletion. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603421.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.4.4 / Adenylosuccinate Synthase
  •  go-up   go-down


58. Tajiri M, Kameda Y, Nakayama H, Sakamoto K: Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area. J Clin Pathol; 2006 Mar;59(3):269-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area.
  • AIM: It has become obvious that the prognosis of bronchioloalveolar cell carcinoma (BAC) in small peripheral adenocarcinoma of the lung is good, but most cases actually treated as pulmonary adenocarcinoma in hospitals tend to be non-bronchioloalveolar cell carcinoma (non-BAC).
  • RESULTS: The NAAR and HAAR were significantly higher in the recurrent cases than in the recurrence free cases.
  • [MeSH-major] Adenocarcinoma / pathology. Bronchial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7950-4 [11691817.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Anal Quant Cytol. 1982 Sep;4(3):225-32 [7149488.001]
  • [Cites] Mod Pathol. 1990 May;3(3):314-20 [2362938.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):904-12 [2403196.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • (PMID = 16505277.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860342
  •  go-up   go-down


59. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Pathological diagnosis of the resected specimen was adenocarcinoma with lymph nodes metastasis.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • But a recurrent lesion at the ovarium was detected 6 months after surgery.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


60. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther; 2006 Aug;5(8):928-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent KRAS codon 146 mutations in human colorectal cancer.
  • We report here the identification of recurrent somatic missense mutations at alanine 146, a highly conserved residue in the guanine nucleotide binding domain.
  • Lung adenocarcinomas and large cell carcinomas did not show codon 146 mutations.
  • [MeSH-minor] Adenocarcinoma / genetics. Amino Acid Sequence. Carcinoma, Large Cell / genetics. DNA Mutational Analysis. DNA, Neoplasm / genetics. Hong Kong. Humans. Leukemia, Myeloid, Acute / genetics. Molecular Sequence Data. Neoplasm Staging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Homology, Amino Acid. United States

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1334-8 [418410.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):143-9 [6290897.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):149-52 [7133135.001]
  • [Cites] Mol Cell Biol. 1988 Jun;8(6):2472-8 [3043178.001]
  • [Cites] Carcinogenesis. 1988 Nov;9(11):2073-9 [2902939.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):405-8 [2403644.001]
  • [Cites] Virus Genes. 1991 Jan;5(1):75-9 [2017878.001]
  • [Cites] Hum Mutat. 1996;8(3):258-61 [8889585.001]
  • [Cites] Mutat Res. 2004 Nov;567(2-3):447-74 [15572290.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1299-304 [11701921.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • (PMID = 16969076.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / CA062924; United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2714972; NLM/ UKMS27311
  •  go-up   go-down


61. Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer; 2010 May;68(2):185-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
  • There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the more common non-small lung carcinoma subtypes.
  • We demonstrated that demographic data, clinical characteristics and stage at presentation (extrathoracic versus lung metastasis, as well as TNM staging) did not distinguish between the two subtypes.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. DNA-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19581016.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Quinazolines; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


62. Takaoka K, Kimura B, Aikawa A, Tokimitsu S, Hashizume M, Kidokoro T, Katou K, Takano T, Yamagishi M, Uchikado M, Itou S, Okano Y, Hanawa Y, Yagi M: [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib]. Gan To Kagaku Ryoho; 2005 Jan;32(1):73-6
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
  • The patient was a 69-year-old male who visited an outpatient clinic because of chronic renal failure and was diagnosed with primary lung cancer.
  • He then underwent an operation for lung cancer, but because it had progressed to stage IV the lesion was not completely resected.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Kidney Failure, Chronic / complications. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use. Respiratory Insufficiency / complications


63. Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol; 2010 Jun;5(6):830-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
  • METHODS: Retrospective analysis of resected BAC reclassified according to the 2004 World Health Organization classification of lung tumors.
  • Sixty six percent (4 of 6) of patients with multifocal disease died (two mucinous BAC and one nonmucinous BAC with recurrent disease).
  • Seventy one percent (5 of 7) of patients with pneumonic-like tumor (all mucinous BAC) died of recurrent/progressive disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


64. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT: Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J; 2005 Apr;52(2):281-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
  • We report the case of a 52-year-old man with the history of two previous thyroid operations for benign goiters, who developed a recurrent goiter.
  • Postoperative I-131-radioiodine scan showed multiple lung and liver metastases, while calcitonin was negative.
  • (1) he suffered a period of severe staphylococcal sepsis with temporal immunosuppression and (2) he worked for long years as a coremaker in a foundry.
  • This work represented possible long term exposure to inhalative carcinogenous toxins like hydrazine, which caused thyroid parafollicular cell adenomas in an animal model.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Recurrence. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863962.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Kim H, Chung SJ, Kim SG, Kim JS, Jung HC, Song IS: Endoscopic Ultrasonography-guided Fine Needle Aspiration for Computed Tomography-negative and Positron Emission Tomography-positive Mediastinal Lymph Node in a Patient with Recurrent Lung Cancer. Gut Liver; 2007 Jun;1(1):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasonography-guided Fine Needle Aspiration for Computed Tomography-negative and Positron Emission Tomography-positive Mediastinal Lymph Node in a Patient with Recurrent Lung Cancer.
  • Herein, we report a case of successful endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) for the diagnosis of CT-negative and PET-positive LN that was found after curative resection in lung cancer.
  • To the best of our knowledge, this is the first description in Korea to perform EUS-FNA for the evaluation of metastatic LN during the follow-up period after lung cancer resection.A 63-years old male patient was diagnosed as a stage T4N0M0 non-small lung cancer.
  • We performed EUS-guided FNA to obtain a biopsy specimen from paraesophageal lymph node, and this proved to be a metastatic adenocarcinoma.
  • In conclusion, EUS-FNA provided minimally invasive confirmation of the metastatic LN in recurrent a lung cancer patient after curative resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2005 Jan 15;171(2):177-82 [15502117.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):263-8 [15620955.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2090-6 [8520780.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Nov;118(5):894-9 [10534695.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):340-6 [15332020.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):628-33 [15089893.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):53-60 [15013583.001]
  • [Cites] Gastrointest Endosc. 1993 May-Jun;39(3):429-31 [8390383.001]
  • (PMID = 20485666.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871648
  • [Keywords] NOTNLM ; Endoscopic ultrasonography / Fine needle aspiration / Lung cancer / Lymph node / Metastasis
  •  go-up   go-down


66. Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N: Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol; 2009 Nov;4(11):1420-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
  • PURPOSE: Pemetrexed is a standard treatment against recurrent non-small cell lung cancer (NSCLC), and cetuximab has single-agent activity against NSCLC.
  • PATIENTS AND METHODS: Patients with recurrent NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1 were entered.
  • Patient characteristics included 60.6% men, median age 64 years (range, 37-80 years), 57.6% had performance status 0 and 54.6% had adenocarcinoma histology.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / administration & dosage. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701110.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


67. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H: Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg; 2009 Mar;394(2):249-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
  • BACKGROUND: Prognosis of the patients with pancreatic adenocarcinoma is still poor due to a recurrence, and liver metastasis is a distant metastasis that is foreboded the short survival period.
  • METHODS: Between 1999 and 2005, 68 patients for pancreatic adenocarcinoma underwent a pancreaticoduodenectomy (n = 17), a pylorus-preserving pancreaticoduodenectomy (n = 27), distal pancreatectomy (n = 22), or total pancreatectomy (n = 2) with an extensive lymph node dissection.
  • RESULTS: A tumor recurrence occurred to 55 patients (13 of the liver, 21 of the local recurrence, 16 of peritoneal dissemination, three of the lymph node, and two of lung).
  • The median survival time (MST) was 13.6 months, and MST of patients with a liver metastasis as an initial recurrent site was 13.7 months; the liver metastasis as an initial recurrent site has no impact on the MST after pancreatic resection.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Node Excision / methods. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Pancreatology. 2002;2(2):79-88 [12123098.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Pancreas. 2002 Nov;25(4):366-72 [12409831.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Surgery. 2004 Nov;136(5):1003-11 [15523393.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):361-4 [7943597.001]
  • [Cites] World J Surg. 1999 Sep;23(9):888-91 [10449815.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):304-9 [14993026.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Eur J Cancer. 1991;27(10 ):1258-63 [1835595.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 2006 Sep;203(3):345-52 [16931307.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):1-7 [16794381.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • (PMID = 18343944.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Leighl NB, Zatloukal P, Mezger J, Ramlau R, Moore N, Reck M, Manegold C: Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol; 2010 Dec;5(12):1970-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
  • INTRODUCTION: The placebo-controlled, phase III AVAiL trial evaluated bevacizumab plus cisplatin and gemcitabine as first-line therapy in patients with advanced, nonsquamous non-small cell lung cancer.
  • Most of the patients were Caucasian (87%) and the majority had adenocarcinoma (83%).
  • CONCLUSIONS: This analysis of the randomized, phase III AVAiL trial shows that bevacizumab-based therapy improves outcomes for elderly patients with non-small cell lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20978447.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00806923
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE: Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer; 2007 Apr 1;109(7):1355-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
  • BACKGROUND: From 20% to 30% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) develop recurrent disease.
  • Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL.
  • Two patients died, 1 secondary to a complication of metastatic lung adenocarcinoma, and the other of sepsis.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17326049.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


70. Maeda T, Tateishi U, Komiyama M, Fujimoto H, Watanabe S, Terauchi T, Moriyama N, Arai Y, Sugimura K, Kakizoe T: Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases. Jpn J Clin Oncol; 2006 Sep;36(9):598-601
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases.
  • In one patient, recurrent tumor of the supraclavicular node (6 mm) diminished in size after subsequent hormone therapy.
  • Surgical resection of recurrent tumor of the lung (12 mm) was performed in the other patient, the pathology of which confirmed the metastatic adenocarcinoma derived from the prostate.
  • The recurrent tumor can be correctly detected by dual-phase whole body [C-11] choline positron emission tomography/computed tomography.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymphatic Metastasis / radionuclide imaging. Pelvic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844733.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Carbon Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


71. Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, Iuchi K, Takada M, Kawahara M, Kawaguchi T, Yukiue H, Yokoyama T, Yano M, Fujii Y: Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol; 2008 May;134(5):569-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
  • To evaluate the epidermal growth factor receptor (EGFR) protein expression, gene mutations and amplification as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC) receiving gefitinib, we have performed fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).
  • We investigated the EGFR amplification and EGFR protein expression statuses in 27 surgically treated non-small-cell lung cancer (NSCLC) cases.
  • EGFR mutations were found from 15/27 lung cancer patients.
  • Smoking status (never smoker vs. smoker, P=0.0032), and pathological subtypes (adenocarcinoma vs. non-adenocarcinoma, P=0.0011), but not EGFR amplification (P=0.1278), were correlated with survival of lung cancers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Drug Resistance, Neoplasm / genetics. Genes, erbB-1. Lung Neoplasms / genetics. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Cancer. 2007 May 1;109(9):1836-44 [17387741.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):375-84 [16199108.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):180-4 [16003726.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):423-9 [17473658.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] BMC Cancer. 2006 Dec 21;6:295 [17184525.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12 (8):2538-44 [16638863.001]
  • (PMID = 17932690.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


72. Gómez-Román JJ, Del Valle CE, Zarrabeitia MT, Martínez JC, Goñi FZ, Lera RM, Cuevas J, Val-Bernal JF: Recurrence of bronchioloalveolar carcinoma in donor lung after lung transplantation: microsatellite analysis demonstrates a recipient origin. Pathol Int; 2005 Sep;55(9):580-4
MedlinePlus Health Information. consumer health - Lung Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of bronchioloalveolar carcinoma in donor lung after lung transplantation: microsatellite analysis demonstrates a recipient origin.
  • Bronchioloalveolar carcinoma is a distinctive subtype of pulmonary adenocarcinoma, without effective therapy, although there have recently been some attempts to use lung transplantation.
  • Presented herein is a case of a bilateral lung transplantation for a bilateral and pneumonic form of non-mucinous bronchioloalveolar carcinoma in a 43-year-old woman.
  • A complete microsatellites molecular analysis was performed to compare the primary and recurrent carcinoma using capillary electrophoresis, showing that the recurrent tumor was generated in a recipient cellular clone.
  • The absence of lymph node metastasis and the molecular evidence of the recipient origin of the neoplasm supports the contamination of the new lungs at the time of implantation as being the reason for the high incidence of recurrence after lung transplantation in this kind of disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / surgery. Lung Transplantation. Microsatellite Repeats. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143034.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


73. Ozlü T, Bülbül Y: Smoking and lung cancer. Tuberk Toraks; 2005;53(2):200-9
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking and lung cancer.
  • The association between cigarettes and lung cancer has been proven by large cohort studies.
  • Tobacco use has been reported to be the main cause of 90% of male and 79% of female lung cancers.
  • 90% of deaths from lung cancer are estimated to be due to smoking.
  • The risk of lung cancer development is 20-40 times higher in lifelong smokers compared to non-smokers.
  • In recent decades, there has been a shift from squamous and small cell lung cancer types to adenocarcinoma, due to increasing rates of smoking among female population and rising light cigarette usage.
  • After smoking cessation, the cumulative death risk from lung cancer decreases.
  • Stopping smoking may prolong survival in cancer patients, and also decreases the risk of recurrent pulmonary carcinoma.
  • [MeSH-major] Lung Neoplasms / prevention & control. Smoking / adverse effects. Smoking Cessation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100660.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 124
  •  go-up   go-down


74. Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR: Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1362-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.
  • The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC).
  • Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients.
  • Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes.
  • Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Ann Intern Med. 2004 May 4;140(9):740-53 [15126259.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20989-94 [12644459.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5361-6 [15328173.001]
  • [Cites] Br J Cancer. 1997;75(10):1509-14 [9166946.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1930-3 [10371572.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(13):1724-30; discussion 1730-1 [16425524.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21546-57 [16728390.001]
  • [Cites] Oncology. 2006;70(3):203-11 [16809939.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Ai Zheng. 2006 Nov;25(11):1361-7 [17094902.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2634-42 [17473194.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):284-9 [17534174.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27424-35 [17627939.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):1S-19S [17873156.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):515-9 [17913444.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5578-83 [18065730.001]
  • [Cites] Histol Histopathol. 2008 Jun;23(6):693-700 [18366007.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]
  • [Cites] Diagn Cytopathol. 2009 Mar;37(3):178-83 [19170169.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2990-5 [19318550.001]
  • [Cites] Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 [19349489.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1032-43 [19430419.001]
  • [Cites] Carcinogenesis. 2009 Nov;30(11):1903-9 [19736307.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2468-73 [11147629.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1524-34 [11927537.001]
  • [Cites] Acta Odontol Latinoam. 2002;15(1-2):29-37 [15208940.001]
  • (PMID = 20447926.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / CA070907-129004; United States / NCI NIH HHS / CA / P20 CA090578-05; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA092824-07; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA90578; United States / NCI NIH HHS / CA / P50 CA070907-129004; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / CA090578-05; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / CA092824-07; United States / NCI NIH HHS / CA / R01 CA074386-11
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / COL23A1 protein, human; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS186813; NLM/ PMC2880394
  •  go-up   go-down


75. Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC: [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer]. Ai Zheng; 2006 Aug;25(8):1035-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
  • BACKGROUND & OBJECTIVE: Although 5-fluarouracil (5-FU)-based chemotherapy has become a standard regimen for treatment of recurrent and metastatic colorectal cancer, the efficacy, as a second line therapy, is not high.
  • This study was to evaluate the short-term effects and toxicity of combination of hydroxycamptothecine (HCPT) plus oxaliplatin (L-OHP) protocol in the treatment of recurrent and metastatic colorectal cancer.
  • METHODS: 47 patients with pathological evidence of recurrent and metastatic colorectal cancer were enrolled and treated with HCPT plus L-OHP regimen for 86 cycles.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Diarrhea / chemically induced. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965689.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


76. Gerritsen KG, Slee PH, Bollen TL, van Hecke W, Seldenrijk CA, Keijsers RG, Duurkens VA: Recurrent pneumonia due to an appendiceal mucinous cystadenocarcinoma: a rare presentation of a rare malignancy. Clin Med Oncol; 2009;3:9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pneumonia due to an appendiceal mucinous cystadenocarcinoma: a rare presentation of a rare malignancy.
  • This is a report of a 74-year-old man who presented with recurrent pneumonia which turned out to be a postobstructive pneumonia complicating a large mucinous cystadenocarcinoma of the appendix with massive retroperitoneal and intrathoracic extension.
  • To the knowledge of the authors, this is the first report of an appendiceal mucinous cystadenocarcinoma with expansion into the thoracic cavity presenting with recurrent pneumonia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):644-7 [16621426.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Jul;24(1):168-70 [12853064.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):585-9; discussion 589-90 [12799327.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] AJR Am J Roentgenol. 2000 Apr;174(4):1005-8 [10749239.001]
  • [Cites] Ann Surg. 1994 Jan;219(1):51-7 [8297177.001]
  • [Cites] Ann Surg. 1938 May;107(5):819-28 [17857185.001]
  • [Cites] Chest. 1990 Dec;98(6):1322-6 [2245668.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):757-68 [7828125.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2289-99 [17541772.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):196-201 [17524597.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):484-92 [17054002.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • (PMID = 20689604.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872597
  • [Keywords] NOTNLM ; appendiceal neoplasms / mucinous adenocarcinoma / recurrent pneumonia / transdiaphragmatic lung invasion
  •  go-up   go-down


77. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA Jr, Hirsch FR: EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol; 2009 Mar;4(3):318-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
  • BACKGROUND: Sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and frequency of activation mutations in EGFR is lower in Caucasian than Asian non small-cell lung cancer (NSCLC) patients.
  • METHODS: A cohort of 44 Japanese patients with recurrent NSCLC after surgery was treated with gefitinib 250 mg daily.
  • Adenocarcinoma was the most common histology (86%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, ras. Lung Neoplasms / genetics. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2890-6 [17504988.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):569-77 [17932690.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5007-18 [16051952.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):907-13 [12610192.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):279-86 [15863375.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2538-44 [16638863.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2158-63 [16682734.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2046-53 [17332333.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):857-63 [17325698.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):629-34 [17409929.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1223-9 [17406029.001]
  • [Cites] Cancer. 2007 May 1;109(9):1836-44 [17387741.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • (PMID = 19247083.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS377989; NLM/ PMC3379811
  •  go-up   go-down


78. Suzuki S, Sekikawa K, Fujita S, Abe N, Ishigame T, Okada R, Gonda K, Saito M, Onogi H, Ohki S, Takenoshita S: [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel]. Gan To Kagaku Ryoho; 2006 Mar;33(3):385-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
  • The patient was a 35-year-old woman with lung, bone and lymphnode metastases of gastric cancer after a total gastrectomy two years earlier.
  • After 3 courses, the size of the lung metastasis was remarkably decreased.
  • This case suggests that combination chemotherapy of weekly paclitaxel and 5'-DFUR might be a promising regimen for recurrent gastric cancer even for patients who show no effect with only paclitaxel administration.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Combined Modality Therapy. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Gastrectomy. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Paclitaxel / administration & dosage. Paclitaxel / pharmacology. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


79. Kadokura M, Kamio Y, Kitami A, Nakajima H, Kushihashi T, Shiokawa A, Nonaka M: [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma]. Kyobu Geka; 2005 May;58(5):361-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma].
  • We report herein a case of CP for a patient with recurrent lung cancer.
  • A 63-year-old man was admitted to our hospital for evaluation of abnormal shadows in the right lung field in October 2002.
  • Right completion pneumonectomy was performed on suspicion of metachronous multiple lung cancers 4 days later.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881232.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Asano M, Matsuo K, Ueda Y, Tsushima M, Mizuta M, Fujiwara K, Yonei T, Sato T: [Pulmonary carcinomatous lymphangiosis from recurrent breast cancer 10 years after resection of the primary tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Jul;47(7):602-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary carcinomatous lymphangiosis from recurrent breast cancer 10 years after resection of the primary tumor].
  • The specimen of transbronchial lung biopsy showed undifferentiated adenocarcinoma cells in lymphatics identified by lymphatic endothelium antibody D2-40 stain, so we diagnosed carcinomatous lymphangiosis.
  • We must keep in mind that some cancers relapse after a long disease-free interval.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lung Neoplasms / secondary. Lymphatic System / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637802.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Mizuno Y, Chin K, Ando N, Oike E: [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1293-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
  • A 57-year-old female was diagnosed as local, lung, and multiple liver metastases in the 2 years and 6 months after surgery.
  • It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Receptor, ErbB-2 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


82. Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M: Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax; 2006 Nov;61(11):1009-10
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma.
  • The case history is presented of a patient with Trousseau's syndrome in which tissue factor originating from lung cancer appeared responsible for recurrent DVT/PE.
  • [MeSH-major] Adenocarcinoma / complications. Lung Neoplasms / complications. Pulmonary Embolism / etiology. Thromboplastin / metabolism. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):109-11 [12853582.001]
  • [Cites] Thromb Haemost. 2003 Oct;90(4):734-7 [14515196.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4):448-51 [14606654.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):472-7 [10027315.001]
  • [Cites] Medicine (Baltimore). 1977 Jan;56(1):1-37 [834136.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):19-22 [9495352.001]
  • [Cites] Surg Today. 2004;34(1):1-5 [14714220.001]
  • (PMID = 17071837.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9035-58-9 / Thromboplastin
  • [Other-IDs] NLM/ PMC2121182
  •  go-up   go-down


83. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol; 2007 Oct 20;25(30):4743-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
  • PURPOSE: Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit in the treatment of non-small-cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Disease-Free Survival. Erlotinib Hydrochloride. Female. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Quinazolines / administration & dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glutamates; 0 / Quinazolines; 0 / Taxoids; 04Q9AIZ7NO / Pemetrexed; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 5Z93L87A1R / Guanine; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


84. Park HS, Kim YI, Kim HY, Zo JI, Lee JH, Lee JS: Bronchial artery and systemic artery embolization in the management of primary lung cancer patients with hemoptysis. Cardiovasc Intervent Radiol; 2007 Jul-Aug;30(4):638-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchial artery and systemic artery embolization in the management of primary lung cancer patients with hemoptysis.
  • PURPOSE: To assess the safety and effectiveness of arterial embolization in lung cancer patients with hemoptysis.
  • METHODS: Nineteen primary lung cancer patients with hemoptysis underwent bronchial artery and systemic artery embolization from April 2002 to March 2005.
  • Histologic analysis revealed squamous cell carcinoma in 10 patients and poorly differentiated adenocarcinoma in 9 patients.
  • The amount of hemoptysis was bleeding of 25-50 ml within 24 hr in 8 patients, recurrent blood-tinged sputum in 6, and bleeding of 100 ml or more per 24 hr in 5.
  • CONCLUSION: Arterial embolotherapy for hemoptysis in patients with primary lung cancer is an effective, safe therapeutic modality despite the fact the vascular changes are subtle on angiography.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / therapy. Bronchi / blood supply. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / therapy. Embolization, Therapeutic. Hemoptysis / therapy. Lung Neoplasms / blood supply. Lung Neoplasms / therapy. Thoracic Arteries

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468904.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA: High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A; 2005 Jul 5;102(27):9625-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiles of human lung cancer.
  • Lung cancer is the leading cause of cancer mortality worldwide, yet there exists a limited view of the genetic lesions driving this disease.
  • In this study, an integrated high-resolution survey of regional amplifications and deletions, coupled with gene-expression profiling of non-small-cell lung cancer subtypes, adenocarcinoma and squamous-cell carcinoma (SCC), identified 93 focal copy-number alterations, of which 21 span <0.5 megabases and contain a median of five genes.
  • Whereas all known lung cancer genes/loci are contained in the dataset, most of these recurrent copy-number alterations are previously uncharacterized and include high-amplitude amplifications and homozygous deletions.
  • Notably, despite their distinct histopathological phenotypes, adenocarcinoma and SCC genomic profiles showed a nearly complete overlap, with only one clear SCC-specific amplicon.
  • Integrated DNA-RNA analyses identified WHSC1L1 and TPX2 as two candidates likely targeted for amplification in both pancreatic ductal adenocarcinoma and non-small-cell lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):465-9 [15037544.001]
  • [Cites] Genomics. 2001 May 15;74(1):79-88 [11374904.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):282-7 [11391799.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1264-7 [11493482.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Blood. 2002 May 15;99(10):3857-60 [11986249.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):224-33 [11979556.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3636-40 [12097266.001]
  • [Cites] Trends Biochem Sci. 2002 Aug;27(8):396-402 [12151224.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6877-83 [12362270.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):857-64 [15033906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4744-8 [15256441.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Histol Histopathol. 1997 Apr;12(2):319-36 [9151120.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2331-5 [9192802.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):79-82 [9591638.001]
  • [Cites] Hum Mol Genet. 1998 Jul;7(7):1071-82 [9618163.001]
  • [Cites] Genomics. 1999 Oct 1;61(1):5-14 [10512675.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4514-9 [11389083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R145-52 [12915456.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1714-21 [14583775.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7113-21 [14612504.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):40-7 [14729606.001]
  • [Cites] Genes Dev. 2004 Jan 15;18(2):126-31 [14729569.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):87-99 [11369051.001]
  • (PMID = 15983384.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084313; United States / NCI NIH HHS / CA / R01 CA099041; United States / NCI NIH HHS / CA / U01-CA084313-07; United States / NCI NIH HHS / CA / R01 CA084628-12; United States / NCI NIH HHS / CA / R01 CA084628; United States / NIA NIH HHS / AG / K08AG 2400401
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / TPX2 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / WHSC1L1 protein, human
  • [Other-IDs] NLM/ PMC1160520
  •  go-up   go-down


86. Lee BE, Port JL, Stiles BM, Saunders J, Paul S, Lee PC, Altorki N: TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg; 2009 Oct;88(4):1100-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNM stage is the most important determinant of survival in metachronous lung cancer.
  • BACKGROUND: Distinguishing a metachronous lung cancer from a metastatic or recurrent lesion in patients with a prior history of non-small cell lung cancer is a challenging task.
  • Previous studies have suggested histologic type and disease-free interval as criteria for diagnosing metachronous lung cancer.
  • These factors may not be as relevant now that current imaging allows for earlier detection of tumors and with the rising incidence of adenocarcinoma.
  • The purpose of this study was to reexamine the factors that determine outcomes in patients with a second primary lung cancer.
  • METHODS: A retrospective review of a prospective lung cancer database was performed to identify patients with metachronous lung cancer.
  • Metachronous lung cancer was defined as any non-small cell lung cancer occurring after a prior resection regardless of disease-free interval or histologic type.
  • RESULTS: Fifty-eight patients had metachronous lung cancer.
  • CONCLUSIONS: These data suggest that early tumor stage is the only significant determinant of survival after surgical treatment of metachronous lung cancer.
  • [MeSH-major] Lung Neoplasms / mortality. Neoplasm Staging / methods. Neoplasms, Second Primary / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S: Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol; 2009 Feb;30(2):367-72
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
  • The purpose of our study was to determine whether relative cerebral blood volume (rCBV), relative peak height (rPH), and percentage of signal-intensity recovery (PSR) derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can distinguish recurrent metastatic tumor from radiation necrosis.
  • Subsequent surgical resection or clinicoradiologic follow-up established a diagnosis of recurrent metastatic tumor or radiation necrosis.
  • RESULTS: The mean, minimum, and maximum PSR values were significantly lower (P < .01) in cases of recurrent metastatic tumor.
  • The mean and maximum rCBV and rPH values were significantly higher (P < .02) in the recurrent metastatic tumor group.
  • CONCLUSIONS: The findings of our study suggest that perfusion MR imaging may be used to differentiate recurrent intra-axial metastatic tumor from gamma knife-induced radiation necrosis.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Contrast Media. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Necrosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022867.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS045013; United States / NCRR NIH HHS / RR / TL1 RR024129-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


88. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M: An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene; 2009 Aug 6;28(31):2773-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
  • To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression with full annotation for major known somatic mutations in this cancer.
  • DUSP4 is involved in negative feedback control of EGFR signaling, and we provide functional validation for its role as a growth suppressor in EGFR-mutant lung adenocarcinoma.
  • DUSP4 loss also associates with p16/CDKN2A deletion and defines a distinct clinical subset of lung cancer patients.
  • These results highlight the power of integrated genomics to identify candidate driver genes within recurrent broad regions of copy number alteration and to delineate distinct oncogenetic pathways in genetically complex common epithelial cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5683-6 [10582684.001]
  • [Cites] PLoS One. 2007;2(5):e426 [17487277.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1807-15 [12759238.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):4-19 [14981576.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1984-91 [15041716.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Mol Biol Cell. 2004 Jul;15(7):3450-63 [15090615.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5697-702 [15184884.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Cancer Lett. 2005 Apr 8;220(2):137-44 [15766588.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3203-13 [17496916.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5667-72 [17575133.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6007-11 [17616654.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5911-8 [17384680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8 [17925434.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):335-9 [18202658.001]
  • [Cites] J Thorac Oncol. 2008 Feb;3(2):111-6 [18303429.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5731-4 [18794081.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):421-30 [16518402.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6033-9 [16778175.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11389-98 [17145885.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4136-51 [17145763.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Genes Dev. 2007 Mar 15;21(6):694-707 [17369402.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):503-12 [17322878.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):77-83 [12573439.001]
  • (PMID = 19525976.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129243-029001; United States / NCI NIH HHS / CA / U01 CA084999; United States / NCI NIH HHS / CA / P01 CA129243-029001; United States / NCI NIH HHS / CA / P01-CA129243; United States / NCI NIH HHS / CA / P01 CA129243; United States / NCI NIH HHS / CA / U01-CA84999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP4 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases
  • [Other-IDs] NLM/ NIHMS108311; NLM/ PMC2722688
  •  go-up   go-down


89. Kojima Y, Yamada Y, Kamisawa H, Sasaki S, Hayashi Y, Kohri K: Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int J Urol; 2006 Aug;13(8):1123-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy.
  • We report a case of recurrent advanced urachal carcinoma with right internal iliac node and left lung metastases in a 34-year-old man.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903943.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


90. Nishio S, Koyanagi T, Miyabe K, Kuromatsu H: [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)]. Gan To Kagaku Ryoho; 2010 Apr;37(4):735-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
  • The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy.
  • Four months later, lung metastases were found.
  • The second patient with stage IIIc poorly-differentiated endometrioid adenocarcinoma of the uterine corpus developed lung metastases 14 months after the initial operation and postoperative chemotherapy.
  • The patient again remained disease-free for four months until lung metastases were observed.
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414038.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


91. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer; 2008 Mar 15;112(6):1325-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
  • BACKGROUND: Aberrant DNA methylation of the CpG islands for cancer-related genes is among the earliest and most frequent alterations in cancer and may be useful for diagnosing cancer or evaluating recurrent disease.
  • The authors determined the frequency of aberrant promoter methylation of 15 genes in 28 resected primary nonsmall cell lung cancers (NSCLCs) and in 12 corresponding nonmalignant lung tissues.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Genes, Tumor Suppressor. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Apoptosis Regulatory Proteins / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Case-Control Studies. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Humans. In Situ Hybridization. Insulin-Like Growth Factor Binding Proteins / genetics. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Inhibitor of Metalloproteinase-3 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18286531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


92. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, Kimura Y, Ishida H, Fujitani K, Narahara H, Shimokawa T: Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol; 2008 Mar;38(3):176-81
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
  • We evaluated the efficacy of this combination in patients with unresectable or recurrent gastric cancer who had been previously treated with S-1.
  • METHODS: Registration was started to enroll 35 patients with advanced/recurrent gastric cancer, who were selected among those with measurable lesions fitting to response evaluation criteria in solid tumors, and with resistant to S-1 treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Anemia / chemically induced. Anorexia / chemically induced. Disease-Free Survival. Drug Combinations. Drug Resistance, Neoplasm. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neutropenia / chemically induced. Oxonic Acid / pharmacology. Peritoneal Neoplasms / secondary. Survival Rate. Tegafur / pharmacology. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281707.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


93. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228810.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


94. Shvartsbeyn M, Edelman MJ: Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1188-90
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed-induced typhlitis in non-small cell lung cancer.
  • Food and Drug Administration-approved as a second line, single-agent treatment of recurrent metastatic non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / adverse effects. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Typhlitis / chemically induced
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / complications. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adult. Female. Humans. Pemetrexed. Thymidylate Synthase / antagonists & inhibitors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827618.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


95. Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y: Video-assisted thoracic surgery for left lung cancer in a patient with a right aortic arch. Gen Thorac Cardiovasc Surg; 2008 May;56(5):239-41
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted thoracic surgery for left lung cancer in a patient with a right aortic arch.
  • We report a rare case of left lung cancer in a patient with a right aortic arch.
  • A 65-year-old woman was diagnosed to have an adenocarcinoma in the left upper lobe (S3) in addition to a right aortic arch (type II), with the left subclavian artery originating from the descending aorta.
  • For the mediastinal dissection, the upper mediastinal lymph nodes were easily resected after verifying the location of the arterial ligament and the recurrent laryngeal nerve (RLN).
  • This is the first report of using VATS to remove a lung cancer from a patient with a right aortic arch.
  • [MeSH-major] Adenocarcinoma / surgery. Aorta, Thoracic / abnormalities. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Female. Humans. Recurrent Laryngeal Nerve / pathology. Subclavian Artery / abnormalities. Tomography, X-Ray Computed. Treatment Outcome. Vocal Cord Paralysis / etiology. Vocal Cord Paralysis / prevention & control

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kyobu Geka. 2003 Aug;56(9):810-3 [12931597.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1995 Aug;43(8):1155-9 [7594851.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Sep;51(9):469-71 [14529170.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 May;27(5):745-52 [15848308.001]
  • [Cites] Ann Thorac Surg. 2002 Mar;73(3):985-6 [11899222.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1966 Jun;97(2):377-89 [5944202.001]
  • (PMID = 18470691.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol; 2005 Apr 10;23(11):2544-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
  • Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC).
  • ResultsForty patients were enrolled and treated in this study (34 patients at phase II dose); the median age was 59 years (range, 36 to 72 years), 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had > or = two prior regimens (three patients had > or = four prior regimens).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


97. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol; 2009 Jan;4(1):30-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
  • BACKGROUND: Enumeration of circulating tumor cells (CTCs) may be valuable for lung cancer treatment and monitoring cancer patient relapse.
  • In the present study we report clinical significance of lung cancer CTC.
  • METHODS: CTCs were enriched from peripheral blood of 47 lung cancer patients by means of a modified enrichment strategy, followed by identification with immunofluorescence staining using anticytokeratins 18 and 19 monoclonal antibodies.
  • Among 41 newly diagnosed and 6 recurrent lung cancer patients (3 stage I-II, 22 stage III and 22 stage IV) including 27 adenocarcinoma (ADC), 7 squamous cell carcinoma and 13 small cell lung cancer (SCLC), positive detection rate of newly diagnosed patients with CTC >/=2/7.5 ml blood was 78% (ADC stage III), 75% (squamous cell carcinoma stage III) and 60% (SCLC stage III), respectively.
  • Recurrent patients showed highest detection sensitivity of 83%.
  • CONCLUSIONS: Results of the present study suggest potential clinical utilities of CTC enumeration on lung cancer patients in terms of rapid evaluation of chemotherapy effect in real time and monitoring lung cancer recurrence.
  • A large scale of study which is necessary for further validation of the significance of lung cancer CTC is being performed.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplastic Cells, Circulating / pathology. Small Cell Lung Carcinoma / pathology
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Case-Control Studies. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratin-18 / blood. Prognosis. Sensitivity and Specificity. Tuberculosis, Pulmonary / blood. Tuberculosis, Pulmonary / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Keratin-18
  •  go-up   go-down


98. Verhagen AF, Bulten J, Shirango H, Thunnissen FB, van der Drift MA, van der Bruggen W, Tjan-Heijnen VC, van Swieten HA: The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer. J Thorac Oncol; 2010 Aug;5(8):1201-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer.
  • INTRODUCTION: In early stage non-small cell lung cancer (NSCLC), presence of lymphatic micrometastases and isolated tumor cells, primarily detected by immunohistochemistry, is suggested to be a prognostic factor.
  • However, there is no consensus whether immunohistochemistry should be used routinely in lymph node assessment.The goal of our study was to determine whether recurrent disease is associated with the presence of lymphatic micrometastases and/or isolated tumor cells, at the time of the lung resection.
  • Group I had a follow-up of 5 years without recurrent disease.
  • Group II consisted of a matched group of patients with recurrent disease.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Large Cell / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Squamous Cell / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588201.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kuroda H, Mochizuki S, Shimoda M, Chijiiwa M, Kamiya K, Izumi Y, Watanabe M, Horinouchi H, Kawamura M, Kobayashi K, Okada Y: ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int J Cancer; 2010 Oct 15;127(8):1844-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
  • ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis.
  • The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001).
  • The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001).
  • There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of <or=20 mm in diameter.
  • The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05).
  • [MeSH-major] ADAM Proteins / blood. Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoma, Large Cell / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Cancer. 2012 Oct 1;131(7):E1180
  • (PMID = 20112342.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM28 protein, human
  •  go-up   go-down


100. Ferrer Rebolleda J, Ortega de los Mártires F, Santos Cores J, Menéndez López A, Arribas Alpuente L, Almenar Medina S: [Contribution of PET in the follow-up of cerebral metastases in non-small cell lung cancer. A clinical case valuation]. Rev Esp Med Nucl; 2006 Mar-Apr;25(2):107-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of PET in the follow-up of cerebral metastases in non-small cell lung cancer. A clinical case valuation].
  • [Transliterated title] Aportación de la PET en el seguimiento de las metástasis cerebrales del cáncer de pulmón no microcítico. Valoración de un caso clínico.
  • We report a clinical case of a male 44 years old with lung adenocarcinoma with a single brain metastases treated with surgery and radiotherapy.
  • The different PET studies performed during the evolution of the disease were very useful and crucial, firstly in the detection of radiation necrosis and after that when cerebral metastases recurrent appeared twice.
  • PET imaging is helpful in selected patients with brain metastases in lung cancer.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / secondary. Frontal Lobe / radionuclide imaging. Lung Neoplasms / pathology. Parietal Lobe / radionuclide imaging. Positron-Emission Tomography






Advertisement